I'm LongbridgeAI, I can summarize articles.METIS TECHBIO-P rose over 11% during the session, and as of the time of publication, it is up 10.67%, priced at HKD 15.12, with a transaction volume of HKD 83.3917 million. In terms of news, recently, according to METIS TECHBIO's official WeChat account, the company has officially signed a joint venture agreement with JOINN to establish a joint venture company called Zhaotai Smart Medicine, working together to create an innovative R&D and industrial manufacturing platform for mRNA drugs. Currently, the first project of the collaboration has been launched. According to the agreement, METIS TECHBIO will provide design and delivery capabilities upstream, with NanoForge achieving targeted delivery to 8 key organs and tissues in the human body. Ms. Feng Yuxia, Chairwoman of JOINN, stated: "The establishment of the joint venture between JOINN and METIS TECHBIO is an important practice of complementary advantages and collaborative development. METIS TECHBIO has outstanding innovative capabilities in AI-driven mRNA sequence design and nano-delivery, while JOINN has solid process development and industrialization experience in the macromolecule drug CDMO field. We hope that through this cooperation, we can effectively integrate both parties' R&D and manufacturing capabilities to jointly provide one-stop services from design to production for mRNA new drug development."
According to Zhitong Finance APP, METIS TECHBIO-P (07666) rose over 11% during the trading session, and as of the time of publication, it was up 10.67%, priced at HKD 15.12, with a transaction volume of HKD 83.3917 million.
In terms of news, recently, according to METIS TECHBIO's official WeChat account, the company has officially signed a joint venture agreement with JOINN to establish a joint venture company called Zhaotai Smart Medicine, working together to create an innovative R&D and industrial manufacturing platform for mRNA drugs. Currently, the first project of the collaboration has been launched. According to the agreement, METIS TECHBIO will provide design and delivery capabilities upstream, and NanoForge has achieved targeted delivery to eight key organs and tissues in the human body.
Ms. Feng Yuxia, Chairman of JOINN, stated: "The establishment of the joint venture company between JOINN and METIS TECHBIO is an important practice of complementary advantages and collaborative development for both parties. METIS TECHBIO has outstanding innovative capabilities in AI-driven mRNA sequence design and nano delivery, while JOINN has accumulated solid process development and industrialization experience in the macromolecule drug CDMO field. We hope that through this cooperation, we can effectively integrate the R&D and manufacturing capabilities of both parties to provide one-stop services from design to production for the R&D of new mRNA drugs."